Drug intelligence / Profile preview

BOLD-200

Development stage: Preclinical
Lead developer: Bold Therapeutics
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Administration: Intravenous

Overview

BOLD-200 is a preclinical-stage next-generation metallotherapeutic being developed by Bold Therapeutics. As a follow-on to the company's lead candidate, BOLD-100, BOLD-200 is part of a proprietary platform of ruthenium-based small molecules designed to treat advanced cancers. While specific molecular targets and primary indications have not been publicly disclosed in detail, the compound is intended to leverage the unique mechanism of action of metallotherapeutics to overcome treatment resistance in solid tumors. It is currently in the discovery or early preclinical phase of development.

Targets

HSPA5 (Heat shock protein family A member 5)

Beyond the preview

Go deeper on BOLD-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOLD-200.

Explore the full profile